Business Context and Reporting Period
This Form 8-K Current Report was filed by Bionano Genomics, Inc. on August 11, 2023, with the earliest event reported on that date. The filing primarily addresses executive leadership changes within the finance function, specifically the departure of the outgoing Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
This filing does not contain operational financial results such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and separation agreements.
Material Changes
Appointment of Chief Financial Officer
- New CFO: Gülsen Kama was appointed as Chief Financial Officer, effective September 11, 2023.
- Compensation Package:
- Base Salary: $460,000 per year.
- Target Bonus: 55% of base salary ($253,000).
- Signing Bonus: $150,000 (contingent on one year of continuous employment).
- Equity: Option to purchase 106,000 shares, vesting over four years (25% cliff, then monthly).
- Severance: In the event of termination without cause or resignation for good reason, Ms. Kama is entitled to six months of base salary, up to six months of COBRA coverage, and accelerated vesting of unvested options if the termination occurs within 24 months of a change in control.
Departure of Chief Financial Officer
- Outgoing CFO: Christopher Stewart resigned effective September 11, 2023.
- Transition: Mr. Stewart will consult for the company through November 11, 2023, at a rate of $500.00 per hour.
- Separation Package:
- Transition Bonus: Lump sum equal to six weeks of base salary.
- Milestone Bonus: Lump sum equal to six weeks of base salary (contingent on strategic milestone by Sept 11, 2023).
- Severance: Cash amount equal to six months of base salary.
- Benefits: COBRA coverage through February 29, 2024.
- Equity: Awards continue to vest through the end of the consulting period.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business performance. The primary risk disclosed relates to the transition of financial leadership and the associated compensation obligations. The company notes that the employment and separation agreements are subject to the execution of customary release of claims.
Investor Verification Checklist
- Verify the effective date of the CFO transition (September 11, 2023) and the interim consulting arrangement.
- Confirm the total immediate cash outlay for the outgoing CFO's separation package (six weeks transition + six weeks milestone + six months severance).
- Review the vesting schedule for the new CFO's 106,000 stock options and the conditions for the $150,000 signing bonus.
- Monitor the upcoming Form 10-Q for the quarter ending September 30, 2023, where the full text of the employment and separation agreements will be filed as exhibits.